$19.44 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
Wall Street analysts expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce sales of $19.44 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global’s earnings, with the lowest sales estimate coming in at $19.18 million and the highest estimate coming in at $19.93 million. Oxford Immunotec Global reported sales of $29.32 million in the same quarter last year, which would suggest a negative year over year growth rate of 33.7%. The company is expected to announce its next quarterly earnings results on Tuesday, July 30th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full-year sales of $70.41 million for the current financial year, with estimates ranging from $70.16 million to $70.58 million. For the next year, analysts anticipate that the business will report sales of $81.49 million, with estimates ranging from $79.32 million to $82.86 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The company’s quarterly revenue was up 26.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.40) earnings per share.
Shares of NASDAQ:OXFD opened at $15.20 on Tuesday. The firm has a market cap of $406.00 million, a PE ratio of 29.80 and a beta of 0.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19.
In related news, CEO Peter Wrighton-Smith sold 10,600 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $16.68, for a total transaction of $176,808.00. Following the completion of the sale, the chief executive officer now owns 445,138 shares in the company, valued at $7,424,901.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Elizabeth M. Keiley sold 4,100 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $17.00, for a total value of $69,700.00. Following the sale, the senior vice president now owns 26,928 shares of the company’s stock, valued at approximately $457,776. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,700 shares of company stock valued at $294,658. 6.61% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of OXFD. Morgan Stanley increased its position in Oxford Immunotec Global by 238.7% in the first quarter. Morgan Stanley now owns 331,731 shares of the company’s stock worth $5,715,000 after buying an additional 233,797 shares in the last quarter. Man Group plc increased its position in Oxford Immunotec Global by 105.6% in the first quarter. Man Group plc now owns 356,624 shares of the company’s stock worth $6,145,000 after buying an additional 183,181 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new stake in Oxford Immunotec Global in the first quarter worth about $35,000. Wellington Management Group LLP increased its position in Oxford Immunotec Global by 22.5% in the first quarter. Wellington Management Group LLP now owns 264,248 shares of the company’s stock worth $4,553,000 after buying an additional 48,598 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Oxford Immunotec Global in the first quarter worth about $1,185,000. Institutional investors own 88.87% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
See Also: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.